By enhancing insulin sensitivity, regulating lipid metabolism, and protecting against cardiac remodeling, NRG4 represents a promising therapeutic target in addressing heart disease, particularly in populations affected by obesity and type 2 diabetes [47,63]. Here, INS is linked to obesity due to melanocortin 4 receptor deficiency.